Columbia Sportswear Company
COLM
$72.19
-0.10%
Columbia Sportswear Company designs, sources, and sells outdoor and active-lifestyle apparel, footwear, equipment, and accessories under four primary brands — Columbia, Sorel, Mountain Hardwear, and prAna — with the bulk of revenue generated in the United States and meaningful contributions from Latin America/Asia-Pacific, EMEA, and Canada, distributed predominantly through wholesale channels (sporting goods and department stores) supplemented by a company-owned retail footprint. As a mid-cap, multi-brand outdoor specialist with roughly 9,600 employees, Columbia occupies a value-to-mid-tier position in the global outdoor apparel market, competing against larger vertically integrated players and premium technical brands while leveraging its broad wholesale distribution and family-controlled ownership structure as a source of stability. The current investor narrative centers on a sharp earnings recovery: after a loss-making Q2 2025, the company has posted three consecutive profitable quarters culminating in a Q3 2026 EPS of $1.67 versus $0.95 a year earlier, with gross margin holding near 50% and revenue returning to modest 2.1% year-over-year growth. That turnaround, combined with a balance sheet carrying essentially no traditional long-term debt and a 2.2% dividend yield, has driven a powerful re-rating in the shares, though sell-side sentiment remains split — UBS maintains a Sell rating while BTIG and Stifel remain Buy-rated — reflecting genuine debate over whether the margin recovery is durable or merely a favorable comparison against a depressed prior-year base.…
COLM
Columbia Sportswear Company
$72.19
Investment Opinion: Should I buy COLM Today?
Rating: Hold, with a constructive lean. The core thesis is that COLM has delivered a genuine, margin-led earnings recovery — Q3 2026 EPS of $1.66 versus $0.95 a year earlier, three consecutive profitable quarters, a debt-free balance sheet (debt-to-equity 0.279, current ratio 2.59) — but at $70.43 the shares already sit at roughly 99% of their 52-week range after a 24.59% one-month rally, and the sell-side is split 2 Buy / 1 Neutral / 1 Sell with no published consensus target to anchor upside. The analyst consensus EPS of $4.03 against the current price implies a forward multiple of roughly 17.5x, essentially flat versus the 17.0x trailing PE, meaning the market is already capitalizing the recovery at the trailing rate.
Supporting evidence is mixed but tilts modestly positive on valuation and strongly positive on balance-sheet quality. On the primary metric, the 17.0x trailing PE is roughly in line with a high-teens sector average, while PS of 0.89x and EV/EBITDA of 10.6x sit well below the 1.5–2.5x sales and 12–15x EBITDA typical of branded apparel peers — a discount that is partly earned by 2.06% revenue growth and a 6.01% TTM operating margin, but wider than a 50.24% gross margin and zero interest expense would justify. Profitability is inflecting: Q3 2026 net income of $84.7 million (8.80% net margin) versus $52.0 million, with Q3 operating margin of 11.39% approaching the historical mid-teens peak. Cash generation is real on an annual basis — TTM FCF of $275.5 million, including $596.8 million in Q4 2025 — even though the Q3 seasonal working-capital swing produced a -$333.0 million outflow. The 2.18% dividend yield and $50 million of Q3 buybacks provide modest carry while the thesis plays out.
Three risks could invalidate the view. First, the recovery is entirely margin-driven: if gross margin fails to hold near 50%, the thin 6.01% operating margin leaves little buffer and the low PS multiple becomes a value trap rather than a cushion. Second, the 24.59% one-month rally has front-run confirmation, so a holiday-quarter miss could trigger a give-back toward the $63–64 breakout base and then the $56.06–$56.32 August–September floor, roughly -20% from current levels. Third, thin coverage (two EPS estimates, no consensus target, UBS at Sell) means price discovery is inefficient and volatility elevated, consistent with the -19.52% max drawdown. This Hold would upgrade to Buy if Q4 holiday gross margin holds at or above 50% and consensus EPS revises above $4.03, or if the stock pulls back toward the $63–64 support zone; it would downgrade to Sell if gross margin slips below roughly 48% or revenue growth turns negative. Verdict: fairly valued relative to its own history and modestly undervalued versus branded peers on sales and EBITDA, but not cheap enough to compensate for the unconfirmed durability of the margin recovery at 52-week highs.
Sign up to view all
COLM 12-Month Price Forecast
The forward view is genuinely balanced: the earnings recovery is real and the balance sheet is debt-free, but the stock at $70.43 has already priced in the recovery, sitting at roughly 99% of its 52-week range after a 24.59% one-month gain that has run ahead of published analyst conviction. The 17.0x trailing PE and roughly 17.5x forward multiple on the $4.03 consensus EPS leave little room for multiple-driven upside, so returns depend on either estimate revisions or continued margin expansion toward the historical mid-teens operating margin from the current 6.01% TTM level. The 55% base-case weight reflects that the most likely outcome is consolidation in the $66–76 range as the holiday quarter validates or modestly disappoints. I would upgrade to bullish if Q4 gross margin holds at or above 50% and consensus EPS moves above $4.03, and downgrade to bearish if gross margin slips below roughly 48% or the stock breaks below the $56–57 floor that defines the recovery structure.
Wall Street consensus
Coverage is thin, with only 2 analysts contributing EPS estimates (average $4.03, range $3.97–$4.08) and consensus revenue of $3.826 billion (range $3.786–$3.865 billion), implying roughly flat-to-modest growth versus the current run-rate. The institutional ratings history shows a genuinely divided tape: BTIG has maintained Buy through 2026 (most recently October 30, 2026), Stifel reiterated Buy on July 31, 2026, Citigroup has stayed Neutral across four updates, and UBS has held a Sell rating throughout — a 2 Buy / 1 Neutral / 1 Sell split that leans mildly positive but with unusually wide dispersion for a mid-cap. No average price target is provided in the dataset, so implied upside cannot be calculated; based on the $4.03 consensus EPS and the current 17.0x multiple, the market is already capitalizing consensus earnings at the trailing rate, suggesting limited multiple-driven upside unless estimates revise higher.
Insufficient analyst coverage and target-price data are available to construct a meaningful range analysis, which itself is informative: with only two EPS estimates and no published consensus target, COLM sits in the small/mid-cap coverage gap (market cap ~$3.0–3.6 billion), where limited institutional attention can produce higher volatility and less efficient price discovery — consistent with the stock's -19.52% max drawdown and its sharp 11.6% two-day post-earnings move. The rating dispersion is the key signal: the Sell case (UBS) likely rests on skepticism that the margin recovery is sustainable given only 2.06% revenue growth and a 6.01% operating margin, while the Buy case (BTIG, Stifel) likely assumes continued gross-margin defense near 50%, working-capital normalization, and multiple re-rating toward peer levels as earnings visibility improves. With no upgrades or downgrades in the recent ratings log — every action is a reiteration — the sell side is in a holding pattern awaiting confirmation from the holiday quarter, and the absence of fresh target revisions means the stock's recent 24.59% one-month rally has run ahead of published analyst conviction.
Bulls vs Bears: COLM Investment Factors
The bull case currently has stronger evidence: earnings have inflected decisively (Q3 EPS $1.66 vs $0.95, net income $84.7 million vs $52.0 million), the balance sheet is effectively debt-free with a 2.59 current ratio, and the stock trades at 0.89x sales — near the low end of its own historical band — even as price sits at 52-week highs. The bear case is not weak, however: 2.06% revenue growth means the recovery is entirely margin-driven, TTM operating margin of 6.01% remains thin, and the sell-side is genuinely split with UBS at Sell and no consensus target to anchor valuation. The single most important tension is whether the gross-margin defense near 50% is structural (sourcing discipline, lower discounting) or merely a favorable comparison against a depressed 2025 base — if Q4 holiday margins hold, the low multiple is a cushion; if they roll over, it becomes a value trap. Secondary tension: the 24.59% one-month rally has front-run confirmation, so the holiday quarter must validate the move or the stock is exposed to a sharp give-back toward the $63–64 breakout base.
Bullish
- Earnings inflected sharply, EPS up 75%: Q3 2026 diluted EPS of $1.66 versus $0.95 a year earlier represents roughly 75% growth, and net income of $84.7 million (8.80% net margin) compares with $52.0 million in Q3 2025. The Q2 2026 profit of $26.6 million also reversed the -$10.2 million loss from Q2 2025, giving three consecutive profitable quarters.
- Debt-free balance sheet, strong liquidity: Debt-to-equity is just 0.279 with a current ratio of 2.59 and $216.9 million of cash at Q3 2026. Interest expense is zero across every reported quarter, and the company funded $50 million of buybacks plus $15.4 million of dividends internally.
- Valuation near low end of own history: PS of 0.89x sits near the depressed 2025 trough level (versus a 5.22x peak in Q2 2026), and EV/EBITDA of 10.6x is well below the 12–15x typical of branded apparel peers. The 17.0x trailing PE is roughly in line with a high-teens sector average despite the recovery.
- Momentum and relative strength decisive: The stock is up 24.59% in one month and 38.75% over the trailing year, outperforming SPY by 29.58 and 29.16 percentage points respectively. The one-month gain exceeds the three-month gain (22.79%), indicating an accelerating inflection rather than a fading move.
Bearish
- Revenue growth barely above zero: Q3 2026 revenue grew only 2.06% year-over-year to $962.6 million, and consensus revenue of $3.826 billion implies roughly flat-to-modest growth versus the current run-rate. The entire thesis rests on margin recovery, not top-line expansion.
- Thin margins versus branded peers: TTM net margin of 5.22% and operating margin of 6.01% are well below best-in-class branded apparel peers, and the weak first half (Q1 operating margin 4.86%, Q2 5.03%) drags trailing figures. The 11.39% Q3 operating margin still trails the 12.52% achieved in Q4 2024.
- Sell-side split with no target support: Coverage is a 2 Buy / 1 Neutral / 1 Sell split with only two EPS estimates and no published consensus price target. UBS has held Sell throughout, and every recent rating action is a reiteration — the 24.59% one-month rally has run ahead of published analyst conviction.
- Stock at 99% of 52-week range: At $70.43 the shares sit just below the $71.12 recent high, roughly 25% above the $56.06–$56.32 August–September floor. The -19.52% max drawdown over the period shows mean-reversion risk is real even within an uptrend.
COLM Technical Analysis
COLM is in a pronounced, sustained uptrend, with the stock up 38.75% over the trailing year and 25.70% year-to-date, dramatically outperforming a flat-to-negative tape (SPY +9.59% over one year, +7.83% YTD). At a current price of $70.43, the shares sit essentially at the top of their 52-week range — the highest close in the provided 180-day series is $71.12 (November 2, 2026), meaning the stock is trading at roughly 99% of its recent range high, a positioning that signals strong momentum but also meaningful short-term overextension risk. The 52-week low implied by the data is near the $56 area (multiple closes in the $56.06–$56.32 zone during August–September 2026), so the stock has recovered approximately 25% off that base, and the maximum drawdown of -19.52% over the period underscores that the path higher has not been linear.
Short-term momentum is decisively positive and accelerating: the stock is up 24.59% over the past month and 22.79% over three months, with the one-month gain actually exceeding the three-month gain, indicating a clear inflection rather than a fading move. This is corroborated by relative strength readings — +29.58 percentage points versus SPY over one month and +27.70 points over three months — showing the outperformance is broadening rather than narrowing. The most recent session added 1.90% on volume of roughly 820,000 shares, and the October 30–November 2 surge (from $63.69 to $71.12, a ~11.6% two-day move) almost certainly reflects a post-earnings reaction to the November 5 Q3 filing, suggesting the fundamental catalyst is now embedded in price and near-term consolidation would be unsurprising.
Key technical levels are well defined: immediate resistance sits at the $71.12 recent high, and a decisive breakout above that level — particularly on above-average volume — would confirm the uptrend's continuation and likely open a move into price discovery. Support is layered at the $63–$64 zone (the late-October breakout base) and, more importantly, at the $56–$57 floor established across August and September, which represents the line in the sand for the bullish thesis; a breakdown below that area would invalidate the recovery structure. Beta is not provided in the dataset, but the -19.52% max drawdown alongside a 38.75% one-year gain implies above-market volatility, and with the stock trading at the very top of its range, position sizing should account for elevated mean-reversion risk even as the primary trend remains firmly higher.
Beta
—
—
Max Drawdown
-19.5%
Largest decline past year
52-Week Range
—
Price range past year
Annual Return
+37.5%
Cumulative gain past year
| Period | COLM Return | S&P 500 |
|---|---|---|
| 1m | +28.1% | -2.4% |
| 3m | +24.9% | -2.3% |
| 6m | +25.0% | +2.8% |
| 1y | +37.5% | +11.3% |
| ytd | +28.8% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
COLM Fundamental Analysis
Revenue is growing again but only modestly: Q3 2026 revenue of $962.6 million rose 2.06% year-over-year versus $943.2 million in Q3 2025, a clear stabilization after the prior-year softness. The multi-quarter trajectory shows sequential rebuilding — $779.0 million in Q1 2026, $614.4 million in Q2 2026, and $962.6 million in Q3 2026 — with the seasonal Q3 peak now exceeding its year-ago counterpart. Segment data shows Apparel, Accessories & Equipment at $743.9 million dwarfing Footwear at $218.7 million, meaning the core apparel franchise (including the Columbia and prAna brands) is the swing factor for growth, while footwear (Sorel) remains the smaller but higher-beta contributor; the low-single-digit top-line growth implies the investment case rests far more on margin recovery than on revenue acceleration.
Profitability has inflected sharply. Q3 2026 net income of $84.7 million (8.80% net margin) compares with $52.0 million a year earlier, and diluted EPS of $1.66 versus $0.95 represents roughly 75% growth; the Q2 2026 profit of $26.6 million also contrasts favorably with the -$10.2 million loss in Q2 2025. Gross margin is the key lever — 49.76% in Q3 2026 versus 49.67% a year ago, but notably below the 58.34% reported in Q2 2026 (a seasonally favorable mix quarter) — while the headline gross margin of 50.24% and operating margin of 6.01% (TTM basis) sit below the 11.39% operating margin achieved in Q3 2026 itself, illustrating how much the weak first half weighs on trailing figures. The Q3 operating margin of 11.39% and EBITDA margin of 13.00% are approaching the company's historical mid-teens peak, suggesting the recovery is real but still has room — or, alternatively, that further expansion may be harder to come by.
Balance-sheet health is a genuine strength: debt-to-equity is just 0.279, the current ratio is a robust 2.59, and cash stood at $216.9 million at Q3 2026 (down from $532.3 million at Q2 due to seasonal working-capital build). Free cash flow is highly seasonal — TTM FCF of $275.5 million masks a -$333.0 million Q3 outflow driven by a $445.3 million working-capital swing (receivables up $379.4 million ahead of holiday shipments) — but the company generated $596.8 million of FCF in Q4 2025 and $101.6 million in Q2 2026, demonstrating strong annual cash generation. ROE of 10.36% is respectable though below the company's historical mid-single-to-high-teens peaks, and with $50 million of buybacks executed in Q3 and $15.4 million of dividends paid, the company is returning capital while still funding operations internally — a low financial-risk profile that supports the valuation premium.
Quarterly Revenue
$962582000.0B
2026-09
Revenue YoY Growth
+2.1%
YoY Comparison
Gross Margin
49.8%
Latest Quarter
Free Cash Flow
$275516000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is COLM Overvalued?
Because net income is positive (TTM EPS of $0.0588 is thin but positive, and Q3 2026 net income of $84.7 million is solidly profitable), the PE ratio is the appropriate primary metric. The trailing PE of 17.0x is modest in absolute terms, but the forward PE of -1.10x (as reported) is not economically meaningful and likely reflects a data artifact or a near-zero forward EPS estimate; using the analyst consensus EPS of $4.03 against the $70.43 price instead implies a forward multiple of roughly 17.5x — essentially flat versus trailing, which tells us the market is not pricing in aggressive near-term earnings growth beyond the recovery already delivered. The PS ratio of 0.89x and EV/EBITDA of 10.64x are the more informative cross-checks for a company with seasonal earnings.
Against the broader apparel/manufacturers peer set, COLM screens cheap on sales and EBITDA: a PS of 0.89x and EV/EBITDA of 10.6x are well below the multiples typically commanded by branded apparel peers (often 1.5–2.5x sales and 12–15x EBITDA), while the 17.0x trailing PE is roughly in line with a sector average in the high-teens. The discount appears justified by the company's low-single-digit revenue growth (2.06% YoY), thin 5.22% net margin, and 6.01% operating margin — all below best-in-class branded peers — but the 50.24% gross margin and debt-free balance sheet argue the discount is wider than the fundamentals warrant, particularly with a 2.18% dividend yield providing carry.
Historical context is the most striking part of the valuation picture: COLM's own PE has ranged from roughly 7.9x (Q4 2025) to over 29x (Q2 2026) and even negative in loss quarters over the past several years, while its PS ratio has swung from about 2.76x (Q4 2025) to 5.22x (Q2 2026). At a current PS of 0.89x and PE of 17.0x, the stock is near the low end of its own historical band on sales — a level last seen during the depressed 2025 trough — even as the price sits at 52-week highs. That divergence (price up, multiple compressed) reflects earnings recovering faster than the share price, and suggests the market is still applying a skeptical multiple to the turnaround rather than pricing in optimistic expectations; the risk is that if margin gains stall, the low multiple becomes a value trap rather than a cushion.
PE
17.0x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 8x~30x
vs. Industry Avg
21.3x
Industry PE ~21.3x*
EV/EBITDA
10.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the fact that the entire earnings recovery is margin-driven rather than revenue-driven. Revenue grew just 2.06% year-over-year in Q3 2026 to $962.6 million, and consensus of $3.826 billion implies essentially flat growth, so any gross-margin slippage flows straight to the bottom line — TTM operating margin is only 6.01% and net margin 5.22%, leaving little buffer. Cash flow is highly seasonal and lumpy: TTM FCF of $275.5 million masks a -$333.0 million Q3 outflow from a $445.3 million working-capital swing, and cash dropped from $532.3 million in Q2 to $216.9 million in Q3. Revenue is also concentrated in the Apparel, Accessories & Equipment segment at $743.9 million versus Footwear at $218.7 million, meaning the core Columbia/prAna franchise is the single swing factor for growth, while the smaller Sorel footwear business carries higher beta to consumer discretionary spending. Finally, the trailing EPS of $0.0588 is razor-thin, so trailing multiples are fragile and any single weak quarter can swing reported profitability dramatically, as the Q2 2025 loss of -$10.2 million demonstrated. Market and competitive risks are dominated by valuation-compression and coverage risk. At 17.0x trailing PE and 10.6x EV/EBITDA the stock is not expensive versus branded peers, but the PS of 0.89x is near the low end of its own historical band precisely because the market discounts the durability of the turnaround — if growth stays at 2%, the multiple is unlikely to re-rate and the stock becomes dependent on earnings alone. Coverage is thin (two EPS estimates, no consensus target, a 2 Buy / 1 Neutral / 1 Sell split), which raises volatility and slows price discovery, consistent with the -19.52% max drawdown and the 11.6% two-day post-earnings move from $63.69 to $71.12. Competitive pressure comes from larger vertically integrated players and premium technical brands in a wholesale channel (sporting goods and department stores) that is structurally challenged, and the company's value-to-mid-tier positioning limits pricing power. Beta is not provided, but the 38.75% one-year gain against SPY's 9.59% and the -19.52% drawdown imply above-market volatility, so sector rotation out of consumer cyclical names would hit COLM disproportionately. The worst-case scenario is a holiday-quarter miss in which gross margin fails to hold near 50%, wholesale reorders slow, and the 24.59% one-month rally unwinds. In that chain, the stock would first retest the $63–64 late-October breakout base, then the $56.06–$56.32 August–September floor — roughly -20% from the current $70.43. A full retracement to the 52-week low area would cost investors about -20% to -21%, and a deeper de-rating toward the low end of the historical PE band (7.9x seen in Q4 2025) applied to consensus EPS of $4.03 would imply a price near $32, though that extreme is unlikely without a renewed loss-making quarter. Realistically, the downside case is a -20% to -25% drawdown to the $53–$56 zone if margin gains stall and the sell-side split resolves toward UBS's Sell.
FAQ
The most severe risk is margin dependence: with revenue growth of only 2.06% and a TTM operating margin of 6.01%, any gross-margin slippage below roughly 48% from the current 49.76% flows straight to the bottom line and would validate the UBS Sell rating. Second is valuation and positioning risk — at $70.43 the stock is at roughly 99% of its 52-week range after a 24.59% one-month gain, and the -19.52% max drawdown shows how quickly the rally can reverse toward the $56–57 floor, about -20%. Third is coverage and price-discovery risk: only two EPS estimates, no consensus target, and a 2 Buy / 1 Neutral / 1 Sell split mean the stock is prone to sharp moves, as seen in the 11.6% two-day post-earnings jump from $63.69 to $71.12. Fourth is cash-flow seasonality and wholesale-channel exposure — the -$333.0 million Q3 FCF outflow and a structurally challenged department-store channel add operational uncertainty.
The base case (55% probability) targets $66–76, assuming revenue growth stays near 2.06%, gross margin holds near 50%, and the multiple stays around 17x trailing on the $4.03 consensus EPS — a range-bound outcome between the $63–64 breakout base and the $71.12 recent high. The bull case (25%) targets $82–88, requiring holiday gross margin at or above 50%, estimate revisions above $4.03, and a re-rating toward peer EV/EBITDA of 12–13x on roughly $290–310 million of forward EBITDA. The bear case (20%) targets $53–58, driven by a holiday miss, gross margin below 48%, and a retracement to the $56.06–$56.32 August–September floor. The base case is most likely because the recovery is real but already reflected in price, and the key assumption is that gross margin holds near 50% through the holiday quarter.
COLM looks fairly valued on earnings and modestly undervalued versus peers on sales and EBITDA. The trailing PE of 17.0x is roughly in line with a high-teens sector average, and using the $4.03 consensus EPS against the $70.43 price implies about 17.5x forward — essentially flat, meaning the market is not pricing in aggressive growth beyond the recovery already delivered. The PS of 0.89x and EV/EBITDA of 10.6x sit well below the 1.5–2.5x sales and 12–15x EBITDA typical of branded apparel peers, and the PS ratio is near the low end of COLM's own historical band (versus a 5.22x peak in Q2 2026). That discount is partly earned by 2.06% revenue growth and a 5.22% net margin, but a 50.24% gross margin and zero interest expense suggest it is wider than fundamentals warrant. The market appears to be paying a fair price while still discounting the durability of the margin recovery — if that skepticism proves wrong, there is room to re-rate.
The risk/reward is balanced rather than compelling at $70.43. On the positive side, earnings inflected sharply (Q3 2026 EPS of $1.66 versus $0.95, net income $84.7 million versus $52.0 million), the balance sheet is effectively debt-free with a 2.59 current ratio, and the stock trades at 0.89x sales and 10.6x EV/EBITDA — a discount to branded apparel peers. Against that, revenue grew only 2.06% year-over-year, the TTM operating margin is just 6.01%, and the shares sit at roughly 99% of their 52-week range after a 24.59% one-month rally, with no published consensus target to anchor upside. The biggest downside risk is a holiday-quarter margin miss that unwinds the rally toward the $56–57 floor, roughly -20%. It is a reasonable buy for valuation-disciplined, patient investors who can tolerate thin coverage and volatility, and a better entry would be a pullback toward the $63–64 breakout base.
COLM is better suited to a medium-to-long-term holding period of at least 12–18 months than to short-term trading. The company is in a mid-stage margin recovery with three consecutive profitable quarters, a debt-free balance sheet, and a 2.18% dividend yield, but earnings visibility is limited by thin coverage and a genuinely split sell-side (2 Buy / 1 Neutral / 1 Sell), which produces sharp short-term swings like the 24.59% one-month rally and the -19.52% max drawdown. The 17.0x trailing and roughly 17.5x forward multiples leave little multiple-driven upside near-term, so returns depend on estimate revisions and margin expansion that will take several quarters to confirm. Short-term traders face elevated mean-reversion risk at 52-week highs with resistance at $71.12 and support at $63–64. A patient investor who can tolerate volatility and wants exposure to a cheap, debt-free consumer cyclical with a recovering margin profile is the best fit.